As of 31 January 2021, Reactor® Generation 1 is no longer in production.

The following research has been performed using the Reactor® Gen 1:

1. (2002 Survey) A third-party survey conducted of 23 emergency room physicians and cardiologists regarding our early prototype and concept of how the Reactor® could improve open chest tube insertion.
2. (SAEM Presentation) – Researchers at the University of Connecticut compared the traditional open chest tube insertion vs the Reactor® in a IRB approved rib model. They found use of the Reactor® improves chest tube insertion…with its ease of use, faster time to insertion, and shorter length of incision when compared with traditional thoracostomy technique.
3. (The American Journal of Surgery) – Researchers at Madigan Army Medical Center published a revolutionary look at the traditional method for treating tension pneumothorax (needle decompression) showing the Reactor® to be significantly superior in time to resolution and final pressure. This research has been presented at the 2017 North Pacific Surgical Association, the 2018 Society for Military Surgeons at SAGES (1st place award), the 2018 Madigan Research Day (1st place award), and the 2018 Military Health System Research Symposium.
4. (American Association for the Surgery of Trauma 2019) – Abstract Presentation – Researchers at William Beaumont Army Medical Center, Dignity Health Chandler Regional Medical Center, and Yale School of Medicine studied the effect of properly placed chest tubes as an effective and reliable treatment for simple pneumothorax.   In military, the ability to safely and reliably perform chest tube insertion far forward combat theatre is considered of significant value.  Researchers found
he bladed trocar [Reactor] was equal in comparison to open thoracostomy in regards to insertion time, pneumothorax resolution, and injury rates. The bladed trocar required a smaller incision compared to tube thoracostomy and may be useful adjunct in simple pneumothorax management.
5. ( Military Medicine 2019 )- Researchers from Madigan Army Medical Center and Scripps Mercy Medical Center discuss the evolution of treatments and technology in trauma care with specific focus on the relatively unchanged protocol for treating tension pneumothorax (tPTX). They acknowledge tPTX as a common cause of trauma-related morbidity or death that is treatable with early recognition and early intervention; however, traditional tube thoracostomy requires a specialized skill set to be confidently applied in resource-scarce situations. The researchers present evidence that the Reactor® device could be rapidly utilized to treat tPTX faster than needle decompression and with efficacy similar to traditional open tube placement and demonstrate how it could be used as a ‘one-step acute treatment capable of transitioning to definitive care of tPTX.’

Research Ideas

If you have ideas for a research project utilizing future generations of the Reactor® or other Sharp Medical Products’ devices, please contact us at